TOP-REAL Study Uses Digital Tools to Detect Toxicities Early in HER2+ Breast Cancer

An international academic study investigating whether remote digital health tools can detect toxicities early and preserve treatment continuity for advanced breast cancer patients was presented on Friday at the ESMO AI & Digital Oncology congress, EQS News reported.

Led by the Spanish cancer clinical research group Solti, in collaboration with Unicancer in France and WSG in Germany, the TOP-REAL trial evaluates proactive monitoring for patients receiving first-line treatment with trastuzumab deruxtecan paired with pertuzumab. The project aims to enroll approximately 300 patients across 60 centers in Spain, France, and Germany, as detailed on ClinicalTrials.gov and reported by Veeva CTV.

“We want patients not only to benefit from advances that allow better control of their disease, but also to live better during treatment,” Dr. Cristina Saura, principal investigator of TOP-REAL and head of the Breast Cancer Unit at Vall d’Hebron University Hospital, told EQS News.

The study specifically focuses on interstitial lung disease or pneumonitis associated with trastuzumab deruxtecan. By utilizing daily oxygen saturation measurements via pulse oximetry and periodic exercise tests, researchers hope to catch physiological shifts before symptoms escalate, according to EQS News.

TOP-REAL broadens its inclusion criteria compared to standard key trials by welcoming selected patients with active brain metastases or an ECOG performance status of 2. “The TOP-REAL trial is contributing to the implementation of trastuzumab deruxtecan and pertuzumab in a real-world setting, a treatment with unprecedented efficacy,” said Dr. Santiago Escrivà, medical oncologist at Vall d’Hebron University Hospital.

Plain Language Patient Insights

  • Proactive Tracking: Patients use smartphones, smartwatches, and pulse oximeters between hospital visits to log symptoms and oxygen levels.
  • Broader Access: The trial deliberately includes patient profiles often left out of standard clinical trials, such as those with active brain metastases.
  • Quality of Life: Questionnaires like the EORTC QLQ-C30 track physical functioning and overall well-being throughout the treatment timeline.

Smartwatches and Apps Track Interstitial Lung Disease Risks

The TOP-REAL trial protocol combines mobile applications—specifically CANKADO or Resilience, depending on the participating medical center—with wearable devices to collect granular data on patients receiving intravenous infusions every three weeks. These platforms enable automated or remote electronic patient-reported outcomes, allowing clinicians to review symptom reports between scheduled clinic appointments.

“Identifying a toxicity early can make a major difference to a patient’s experience during treatment,” Dr. Saura told EQS News. Rather than waiting for an in-person consultation to report adverse events, the monitoring model triggers alerts that support prompt clinical assessment.

The trial also explores treatment rechallenge options for patients who discontinue therapy for reasons other than progressive disease or grade 2 or higher pneumonitis. Blood samples and tumor biopsies gathered at baseline and disease progression will help researchers analyze biological markers linked to therapeutic response and adverse events, as outlined on ClinicalTrials.gov.

“TOP-REAL offers a unique opportunity to integrate innovative, patient-centred supportive care pathways into a clinical trial,” said Dr. Inês Vaz-Luis, medical oncologist and researcher at Gustave Roussy. The study is sponsored by Solti and supported by financial and operational backing from AstraZeneca and Daiichi Sankyo, alongside its European academic partners.

Study Parameter Protocol Details
Target Enrollment Approximately 300 patients across Spain, France, and Germany
Core Medications Trastuzumab deruxtecan (5.4 mg/kg IV q3w) plus pertuzumab
Monitoring Hardware Smartwatch, pulse oximeter, and mobile application (CANKADO or Resilience)
Tumor Assessment Schedule Every 9 weeks for the first 12 months, then every 12 weeks

Severe Lung Disease History Limits Rechallenge Options

Patients with a prior history of severe interstitial lung disease or grade 2 or higher pneumonitis linked to antibody-drug conjugates require careful evaluation and may be restricted from certain protocol-defined rechallenge options.

Spain, the fourth-most populous European Union member state, spans the majority of the Iberian Peninsula and includes the Canary Islands, the Balearic Islands, and the autonomous cities of Ceuta and Melilla in North Africa. Its capital is Madrid.

The territory was deeply Romanised as the province of Hispania before the Visigoths established a kingdom centred on Toledo. In the early 8th century, the Umayyad Caliphate conquered most of the peninsula, establishing Al-Andalus centred on Córdoba.

“We need to pay growing attention to how they live during that time,” Dr. Saura told EQS News regarding patients undergoing advanced cancer therapies.

References

  • EQS News Corporate Announcement: TOP-REAL study presentation at ESMO AI & Digital Oncology 2026.
  • ClinicalTrials.gov: NCT07371585 Study Details for Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management.
  • Veeva CTV: Study protocol and intervention parameters for NCT07371585.
Photo of author

Health Desk

Health Desk at Archyde.

Canadá Returns to Davis Cup Final 8 After Wins Over Brazil and France